Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pfizer stock in Canada | $43.94

Own Pfizer shares in just a few minutes.

Pfizer Inc
NYSE: PFE - USD
DRUG MANUFACTURERS-GENERAL
$43.94
- $0.25 ( - 0.57%)

Pfizer is a drug manufacturers-general business based in the US. Pfizer stocks (PFE.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $44.19 – an increase of 0.11% over the previous week. Pfizer employs 78,500 staff and has a trailing 12-month revenue of around $55.5 billion.

How to buy Pfizer stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: PFE in this case.
  5. Research Pfizer stocks. The platform should provide the latest information available.
  6. Buy your Pfizer stocks. It's that simple.

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Pfizer's stock price?

Since the stock market crash in March caused by coronavirus, Pfizer's stock price has had significant positive movement.

Its last market close was $43.94, which is 18.71% up on its pre-crash value of $35.72 and 57.60% up on the lowest point reached during the March crash when the stocks fell as low as $27.88.

If you had bought $1,000 worth of Pfizer stocks at the start of February 2020, those stocks would have been worth $759.54 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,171.44.

Pfizer stock price

Use our graph to track the performance of PFE stocks over time.

Pfizer stocks at a glance

Information last updated 2021-09-24.
Latest market close$43.94
52-week range$31.7629 - $51.86
50-day moving average $46.5257
200-day moving average $40.7688
Wall St. target price$46.17
PE ratio 18.7617
Dividend yield $1.54 (3.48%)
Earnings per share (TTM) $2.342

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Pfizer price performance over time

Historical closes compared with the last close of $43.94

1 week (2021-09-17) 0.11%
1 month (2021-08-25) -7.51%
3 months (2021-06-25) 12.72%
6 months (2021-03-25) 23.18%
1 year (2020-09-25) 21.89%
2 years (2019-09-25) 22.40%
3 years (2018-09-25) 0.34%
5 years (2016-09-23) 28.25%

Is Pfizer under- or over-valued?

Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfizer's P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Pfizer stocks trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.

Pfizer's PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9004. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Pfizer's EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.1 billion.

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

Pfizer financials

Revenue TTM USD$55.5 billion
Operating margin TTM 27.32%
Gross profit TTM USD$33.3 billion
Return on assets TTM 5.45%
Return on equity TTM 18.35%
Profit margin 23.8%
Book value $12.51
Market capitalisation USD$246.4 billion

TTM: trailing 12 months

How to short and sell Pfizer stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "PFE.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 58.7 million Pfizer stocks held short by investors – that's known as Pfizer's "short interest". This figure is 7.7% up from 54.5 million last month.

There are a few different ways that this level of interest in shorting Pfizer stocks can be evaluated.

Pfizer's "short interest ratio" (SIR)

Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer stocks currently shorted divided by the average quantity of Pfizer stocks traded daily (recently around 45.8 million). Pfizer's SIR currently stands at 1.28. In other words for every 100,000 Pfizer stocks traded daily on the market, roughly 1280 stocks are currently held short.

However Pfizer's short interest can also be evaluated against the total number of Pfizer stocks, or, against the total number of tradable Pfizer stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pfizer's short interest could be expressed as 0.01% of the outstanding stocks (for every 100,000 Pfizer stocks in existence, roughly 10 stocks are currently held short) or 0.0105% of the tradable stocks (for every 100,000 tradable Pfizer stocks, roughly 11 stocks are currently held short).

Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Pfizer.

Find out more about how you can short Pfizer stock.

Pfizer's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Pfizer's total ESG risk score

Total ESG risk: 33.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 01/01/2019) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Pfizer's environmental score

Environmental score: 7/100

Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Pfizer's social score

Social score: 18.47/100

Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Pfizer's governance score

Governance score: 13.68/100

Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Pfizer's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Pfizer Inc was last rated for ESG on: 2019-01-01.

Total ESG score 33.15
Total ESG percentile 60
Environmental score 7
Environmental score percentile 6
Social score 18.47
Social score percentile 6
Governance score 13.68
Governance score percentile 6
Level of controversy 3

Pfizer stock dividends

49%

Dividend payout ratio: 48.73% of net profits

Recently Pfizer has paid out, on average, around 48.73% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.53% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 3.53% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.54 per share.

While Pfizer's payout ratio might seem fairly standard, it's worth remembering that Pfizer may be investing much of the rest of its net profits in future growth.

Pfizer's most recent dividend payout was on 7 September 2021. The latest dividend was paid out to all shareholders who bought their stocks by 4 November 2021 (the "ex-dividend date").

Have Pfizer stocks ever split?

Pfizer stocks were split on a 1054:1000 basis on 17 November 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer stocks – just the quantity. However, indirectly, the new 5.1% lower stock price could have impacted the market appetite for Pfizer stocks which in turn could have impacted Pfizer's stock price.

Pfizer stock price volatility

Over the last 12 months, Pfizer's stocks have ranged in value from as little as $31.7629 up to $51.86. A popular way to gauge a stock's volatility is its "beta".

PFE.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.679. This would suggest that Pfizer's stocks are less volatile than average (for this exchange).

Pfizer overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; Arvinas, Inc.; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site